---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-013048"
form_type: "8-K"
ticker: "RNLXY"
cik: "0001811115"
company_name: "Renalytix plc"
filed_at: "2024-02-09T23:59:59+00:00"
generated_at: "2026-06-06T04:56:42.934515+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CMS publishes draft LCD for KidneyIntelX; coverage for type 2 diabetes and CKD stages 1-3b

## Summary
- CMS draft LCD covers KidneyIntelX and kidneyintelX.dkd for patients with type 2 diabetes and Stage 1–3b chronic kidney disease.
- Medicare price set at $950 per test; distinct CPT codes on 2024 Clinical Lab Fee Schedule.
- 45-day public comment period opened Feb 8, 2024; ends March 23, 2024; final LCD expected in 2024.
- Company formally requested the LCD from NGS and submitted peer-reviewed evidence; expert panel meeting held Aug 29, 2023.

## SEC filing metadata
- accession: 0000950170-24-013048
- form_type: 8-K
- ticker: RNLXY
- cik: 0001811115
- company_name: Renalytix plc
- filed_at: 2024-02-09T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811115/000095017024013048/0000950170-24-013048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811115/000095017024013048/rnlx-20240209.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-013048
- JSON: https://secwatch.observer/filing/0000950170-24-013048.json
- Plain text: https://secwatch.observer/filing/0000950170-24-013048.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.